Clinical Trials List
2014-04-07 - 2017-12-31
Phase III
Terminated4
ICD-10C88.8
Other malignant immunoproliferative diseases
ICD-10C94.40
Acute panmyelosis with myelofibrosis not having achieved remission
ICD-10C94.41
Acute panmyelosis with myelofibrosis, in remission
ICD-10C94.42
Acute panmyelosis with myelofibrosis, in relapse
ICD-10C94.6
Myelodysplastic disease, not classified
ICD-10D46.9
Myelodysplastic syndrome, unspecified
ICD-10D46.A
Refractory cytopenia with multilineage dysplasia
ICD-10D46.B
Refractory cytopenia with multilineage dysplasia and ring sideroblasts
ICD-10D46.C
Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
ICD-10D46.Z
Other myelodysplastic syndromes
ICD-10D47.1
Chronic myeloproliferative disease
ICD-10D47.3
Essential (hemorrhagic) thrombocythemia
ICD-10D47.9
Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
ICD-10D47.Z1
Post-transplant lymphoproliferative disorder (PTLD)
ICD-10D47.Z9
Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
ICD-9238.7
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
350 participants
